Article Text

Download PDFPDF
EP1278 Sentinel lymph node technique in early stage ovarian cancer (SENTOV): a phase II clinical trial
  1. V Lago,
  2. P Bello,
  3. B Montero,
  4. L Matute,
  5. S Lopez,
  6. T Marina,
  7. M Agudelo and
  8. S Domingo
  1. University Hospital La Fe, Valencia, Spain


Introduction/Background There is limited evidence that favours the use of the sentinel lymph node (SLN) technique in ovarian cancer. A standardised approach has not been studied. The objective of the present study was to determine the safety and feasibility of the SLN technique by applying a clinical algorithm.

Methodology Twenty patients with histologically confirmed ovarian cancer were prospectively included. 99mTc and indocyanine green were injected into the ovarian and infundibulopelvic ligament stump. An intraoperative mobile gamma camera, a gamma probe and near-infrared fluorescence imaging were used for SLN detection.

Results The SLN technique was performed in 20 patients. The SLN detection rate at both the pelvic and para-aortic region was 19/20 (95%); this value represented a 100% SLN detection rate at the pelvic and/or para-aortic region. The SLN migration and tracer distribution rates of SLN were 100% for 99mTc + ICG, 100% for 99mTc alone and 95% for ICG alone. The mean number of harvested SLNs was 2.2 ± 1.5 (range 0–5) nodes in the pelvic field and 3.3 ± 1.8 (range 1–7) nodes in the para-aortic region. There were no adverse events reported during surgery or the 30-day post-surgery.

Conclusion Detection of SLN in early-stage ovarian cancer appears to be a safe and feasible technique (NCT03452982).

Disclosure Nothing to disclose

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.